Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men.
Caro L, de Hoon J, Depré M, Cilissen C, Miller J, Gao W, Panebianco D, Guo Z, Troemel SL, Anderson MS, Uemura N, Butterton J, Wagner J, Wright DH. Caro L, et al. Among authors: anderson ms. Clin Transl Sci. 2017 Nov;10(6):480-486. doi: 10.1111/cts.12482. Epub 2017 Aug 10. Clin Transl Sci. 2017. PMID: 28796416 Free PMC article. Clinical Trial.
Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection.
Gao W, Webber AL, Maxwell J, Anderson M, Caro L, Chung C, Miltenburg AMM, Popa S, Van Dyck K, Wenning L, Mangin E, Fandozzi C, Railkar R, Shire NJ, Fraser I, Howell B, Talal AH, Stoch SA. Gao W, et al. Clin Pharmacol Ther. 2020 Jun;107(6):1325-1333. doi: 10.1002/cpt.1737. Epub 2020 Feb 8. Clin Pharmacol Ther. 2020. PMID: 31868916 Clinical Trial.
Altered Purinergic Signaling and CD8+ T Cell Dysregulation in STAT3 GOF Syndrome.
Duran JSC, Sayed S, Dalalo MC, Mauracher AA, Knight MS, Conrey PE, Schultz AB, Hay CA, Lindell RB, Howard CA, Abrams ED, Schmitt EG, Thelin MA, Bluestein S, Seroogy CM, Pozos TC, Thatayatikom A, Lundgren I, Gauthier A, Canna SW, Su HC, Keller MD, Delmonte OM, Satter LRF, Holland SM, Bergerson JRE, Leiding JW, Romberg N, Freeman AF, Villarino AV, Anderson MS, Cooper MA, Vogel TP, Henrickson SE. Duran JSC, et al. Among authors: anderson ms. bioRxiv [Preprint]. 2024 Dec 13:2024.12.12.626682. doi: 10.1101/2024.12.12.626682. bioRxiv. 2024. PMID: 39713308 Free PMC article. Preprint.
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response.
Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A, Daud AI. Quandt Z, et al. Among authors: anderson ms. BJC Rep. 2024 Jun 24;2(1):46. doi: 10.1038/s44276-024-00057-7. BJC Rep. 2024. PMID: 39516257 Free PMC article.
455 results